Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium (Nasdaq: EQ) reported first quarter 2026 results and key updates centered on lead candidate EQ504.
The company plans a Phase 1 proof-of-mechanism study for EQ504 in mid-2026 with data about six months later, completed a $35 million private placement, appointed Snehal Naik, Ph.D. as Chief Development Officer, reduced operating expenses and net loss versus 2025, and ended the quarter with $61.3 million in cash, which is expected to fund currently planned operations into 2029.
Equillium (Nasdaq: EQ) announced inducement grants on May 1, 2026 under its 2024 Inducement Plan. The Compensation Committee awarded nonstatutory stock options to purchase an aggregate of 800,000 common shares to two new employees.
Each option’s exercise price equals $2.08 (Equillium’s closing price on May 1, 2026). Options vest over four years: 25% after one year, then monthly over 36 months, subject to continued service and plan/agreement terms, and were approved as an inducement under Nasdaq Listing Rule 5635(c)(4).
Equillium (Nasdaq: EQ) announced that management will present at Oppenheimer’s 2026 Innovation on the Island event on Tuesday, April 28, 2026 at 7:50am AST.
Members of management will be available for investor meetings for registered attendees, providing an opportunity for investor engagement and company updates.
Equillium (Nasdaq: EQ) announced that preclinical data for EQ504 will be presented as posters at IMMUNOLOGY2026™, April 15-19 in Boston. Two posters focus on EQ504 as a potent AhR modulator promoting immune tolerance (IL-10/IL-22) and epithelial barrier repair.
Presentations occur April 16 (Poster 242; speaker 2:30-3:30 PM EDT) and April 18 (Poster 517; speaker 11:30 AM-12:30 PM EDT); posters will be posted on the company Presentations page after each session.
Equillium (Nasdaq: EQ) announced an inducement grant on April 1, 2026: the Compensation Committee awarded a nonstatutory stock option for 32,000 shares to a new employee under the company’s 2024 Inducement Plan.
The option’s exercise price equals $2.04 (closing price on April 1, 2026) and vests over four years: 25% after one year then monthly over 36 months, subject to continued service and plan terms.
Equillium (Nasdaq: EQ) reported fourth-quarter and full-year 2025 results and recent corporate and clinical highlights on March 25, 2026. Key points: no revenue in 2025 versus $41.1M in 2024; FY net loss $22.4M (−$0.39/share); cash and short-term investments $30.3M at Dec 31, 2025; completed a $35M private placement in March 2026 and an up to $50M financing in Aug 2025. Company plans to initiate a Phase 1 proof-of-mechanism study for EQ504 in mid-2026 with data expected ~six months later and expects cash runway into 2029.
Equillium (Nasdaq: EQ) announced management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on March 23, 2026 at 8:30am PT. The company said members of management will also be available for investor meetings with conference registrants.
This presentation offers investors direct access to management and updates on corporate strategy and development plans.
Equillium (Nasdaq: EQ) entered a definitive securities purchase agreement with RA Capital Management to raise approximately $35 million gross through a PIPE announced March 13, 2026. The company will issue roughly 18.9 million shares (including pre-funded warrants) at about $1.854 per share.
Net proceeds are intended to advance clinical development of EQ504, support working capital and general corporate purposes, and are expected to extend the company’s cash runway into 2029. RA Capital received customary Form S-3 resale registration rights.
Equillium (Nasdaq: EQ) announced management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.
Members of management will also be available for investor meetings with registered conference attendees.
Equillium (Nasdaq: EQ) granted inducement stock options to two new employees on January 30, 2026 for an aggregate of 59,750 shares under its 2024 Inducement Plan. Each option has an exercise price of $1.42 (closing price on January 30, 2026) and vests over four years.
Vesting: 25% on the one-year anniversary, then monthly over 36 months, subject to continued service and plan/agreement terms.